Skip to main content.
Menu

Brian Overstreet

Picture of William Heisel

A new company aims to clean up the FDA's messy data for reporting drug adverse events and market it to pharma and other businesses. Health reporters can benefit from the company's work, too.

Picture of William Heisel

Why is the FDA'S adverse events drug database in such a shambles? Scientist Keith Hoffman explains — and talks about how his company has found a business opportunity in that messy data.

Picture of R. Jan Gurley

A new start-up is mining the FDA's adverse event data for medications and finding potentially dangerous patterns that the regulatory agency hasn't addressed — but should.

CONNECT WITH THE COMMUNITY